Bacteriophage-mediated protein delivery into the central nervous system and its application in immunopharmacotherapy

Bibliography

• KOOB GF: Neurobiology of addiction. Toward the development of new therapies. Ann. NY Acad. Sci. (2000) 909:170–185.
   PubMed Web of Science ®Google Scholar
• WEISS F, KOOB GF: Drug addiction: functional neurotoxicity of the brain reward systems. Neurotoxic Res. (2001) 3:145–156.
   PubMedGoogle Scholar
• MELICHAR JK, DAGLISH MR, NUTT DJ: Addiction and withdrawal--current views. Curr. Opin. Pharmacol (2001) 1:84–90.
   PubMedGoogle Scholar
• SPANAGEL R, WEISS F: The dopamine hypothesis of reward: past and current status. Trends Neurosci. (1999) 22:521–527.
   PubMed Web of Science ®Google Scholar
• DI CHIARA G: The role of dopamine in drug abuse viewed from the perspective of its role in motivation. Drug Alcohol Depend. (1995) 38:95–137.
   PubMed Web of Science ®Google Scholar
• JOHANSON CE, FISCHMAN MW: The pharmacology of cocaine related to its abuse. Pharmacol Rev. (1989) 41:3–52.
   PubMed Web of Science ®Google Scholar
• BLAINE JD, LING W: Psychopharmacologic treatment of cocaine dependence. Psychopharmacol Bull. (1992) 28:11–14.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED: Preliminary estimates from the 1992 Household Survey on Drug Abuse. Substance Abuse and Mental Health Service Administration. Office of Applied Studies. Washington, DC: US Department of Health and Human Services, Public Health Services, Advance Report No. 3, June 1993 (1993).
   Google Scholar
• CREGLER LL, HERBERT M: Medical complications of cocaine abuse. N Engl. J. Med. (1986) 315:1495–1500.
   PubMed Web of Science ®Google Scholar
• DES JARLAIS DC, FRIEDLAND SR: AIDS and IV drug use. Science (1989) 245:578–579.
   PubMed Web of Science ®Google Scholar
• LEE JH, BENNETT G: Substance abuse in adulthood. In: Substance Abuse: Pharmacologic, Developmental and Clinical Perspectives. Bennett G, Woolf D (Eds), Wiley, New York, USA (1991):157–170.
   Google Scholar
• WALSH SL: Behavioral pharmacology of cocaine. In: Handbook of Substance Abuse: Neurobehavioral Pharmacology. Tarter RE, Ammerman RT, Ott PJ (Eds), Plenum, New York, USA (1998):187–200.
   Google Scholar
• MENDELSON JH, MELLO NK: Management of cocaine abuse and dependence. N Engl. J. Med. (1996) 334:965–972.
   PubMed Web of Science ®Google Scholar
• GORELICK DA: Pharmacologic interventions for cocaine, crack, and other stimulant addiction. In: Principles of Addiction Medicine. Graham AW, Schultz, TK (Eds), American Society of Addiction Medicine, Chevy Chase (2003):89–111.
   Google Scholar
• GORELICK DA, GARDNER EL, XI ZX: Agents in the development for the management of cocaine abuse. Drugs (2004) 64:1547–1573.
   PubMed Web of Science ®Google Scholar
• LEIDERMAN DB, SHOPTAW S, MONTGOMERY A et al.: Cocaine rapid efficacy screening trial (CREST): a paradigm for the controlled evaluation of candidate medications for cocaine dependence. Addiction (2005) 100\(Suppl. 1):1–11.
   Google Scholar
• WINHUSEN TM, SOMOZA EC, HARRER JM et al.: A placebo-controlled screening trial of tiagabine, sertraline and donepezil as cocaine dependence treatments. Addiction (2005) 100\(Suppl. 1):68–77.
   Google Scholar
• GONZALEZ G, SEVARINO K, SOFUOGLU M et al.: Tiagabine increases cocaine-free urines in cocaine-dependent methadone-treated patients: results of a randomized pilot study. Addiction (2003) 98:1625–1632.
   PubMed Web of Science ®Google Scholar
• CARROLL KM, FENTON LR, BALL SA et al.: Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: a randomized placebo-controlled trial. Arch. Gen. Psychiatry (2004) 61:264–272.
   PubMed Web of Science ®Google Scholar
• HOUTSMULLER EJ, NOTES LD, NEWTON T et al.: Transdermal selegiline and intravenous cocaine: safety and interactions. Psychopharmaco/ogy (2004) 172:31–40.
   PubMed Web of Science ®Google Scholar
• SHOPTAW S, YANG X, ROTHERAM-FULLER EJ et al.: Randomized placebo-controlled trial of baclofen for cocaine dependence: preliminary effects for individuals with chronic patterns of cocaine use. J. Clin. Psychiatry (2003) 64:1440–1448.
   PubMed Web of Science ®Google Scholar
• KAMPMAN KM, PETTINATI H, LYNCH KG et al.: A pilot trial of topiramate for the treatment of cocaine dependence. Drug Alcohol Depend. (2004) 75:233–240.
   PubMed Web of Science ®Google Scholar
• KAMPMAN KM, VOLPICELLI JR, MULVANEY F et al.: Effectiveness of propranolol for cocaine dependence treatment may depend on cocaine withdrawal symptom severity. Drug Alcohol Depend. (2001) 63:69–78.
   PubMed Web of Science ®Google Scholar
• HOFFMAN JA, CAUDILL BD, KOMAN JJ 3rd, LUCKEY JW, FLYNN PM, HUBBARD RL: Comparative cocaine abuse treatment strategies: enhancing client retention and treatment exposure. J. Addict. Dis. (1994) 13:115–128.
   PubMed Web of Science ®Google Scholar
• CASHMAN JR: Biocatalysts in detoxication of drugs of abuse. NIDA Research Monograph (1997) 173:225–258.
   PubMedGoogle Scholar
• CARRERA MR, ASHLEY JA, PARSONS LH, WIRSCHING P, KOOB GF, JANDA KD: Suppression of psychoactive effects of cocaine by active immunization. Nature (1995) 378:727–730.
   PubMed Web of Science ®Google Scholar
• ••This report describes the first successful useof immunopharmacotherapy for the treatment of drug addiction.
   Google Scholar
• CARRERA MR, ASHLEY JA, ZHOU B, WIRSCHING P, KOOB GF, JANDA KD: Cocaine vaccines: antibody protection against relapse in a rat model. Proc. Natl. Acad. Sci. USA (2000) 97:6202–6206.
   PubMed Web of Science ®Google Scholar
• CARRERA MR, ASHLEY JA, WIRSCHING P, KOOB GF, JANDA KD: A second-generation vaccine protects against the psychoactive effects of cocaine. Proc. Natl. Acad. Sci. USA (2001) 98:1988–1992.
   PubMed Web of Science ®Google Scholar
• FOX BS, KANTAK KM, EDWARDS MA et al.: Efficacy of a therapeutic cocaine vaccine in rodent models. Nat. Med. (1996) 2:11129–1132.
   Google Scholar
• KANTAK KM, COLLINS SL, LIPMAN EG, BOND J, GIOVANONI K, FOX BS: Evaluation of anti-cocaine antibodies and a cocaine vaccine in a rat self-administration model. Psychopharmacology (2000) 148:251–262.
   PubMed Web of Science ®Google Scholar
• LANDRY DW, ZHAO K, YANG GX, GLICKMAN M, GEORGIADIS TM: Antibody-catalyzed degradation of cocaine. Science (1993) 259:1899–1901.
   PubMed Web of Science ®Google Scholar
• •This report details the first example of a catalytic antibody capable of degrading cocaine.
   Google Scholar
• CASHMAN JR, BERKMAN CE, UNDERINER GE: Catalytic antibodies that hydrolyze (-)-cocaine obtained by a high-throughput procedure. J. Pharm. Exp. Ther. (2000) 293:952–961.
   PubMed Web of Science ®Google Scholar
• YANG G, CHUN J, ARAKAWA-URAMOTO H et al.: Anti-cocaine catalytic antibodies: a synthetic approach to improved antibody diversity./ Am. Chem. Soc. (1996) 118:5880–5890.
   Google Scholar
• BAIRD TJ, DENG SX, LANDRY DW, WINGER G, WOODS JH: Natural and artificial enzymes against cocaine. I. Monoclonal antibody 15A10 and the reinforcing effects of cocaine in rats. J. Pharmacol Exp. Ther. (2000) 295:1127–1134.
   Google Scholar
• MATSUSHITA M, HOFFMAN TZ, ASHLEY JA, ZHOU B, WIRSCHING P, JANDA KD: Cocaine catalytic antibodies: the primary importance of linker effects. Bioorg. Med. Chem. Lett. (2001) 11:87–90.
   PubMed Web of Science ®Google Scholar
• ISOMURA S, HOFFMAN TZ, WIRSCHING P, JANDA KD: Synthesis, properties, and reactivity of cocaine benzoylthioester possessing the cocaine absolute configuration./ Am. Chem. Soc. (2002) 124:3661–3668.
   PubMed Web of Science ®Google Scholar
• MEIJLER MM, MATSUSHITA M, WIRSCHING P, JANDA KD: Development of immunopharmacotherapy against drugs of abuse. Curr. Drug Discov. Tech. (2004) 1:77–89.
   PubMedGoogle Scholar
• GORELICK DA: Enhancing cocaine metabolism with butyrylcholinesterase as a treatment strategy. Drug Alcohol Depend. (1997) 48:159–165.
   PubMed Web of Science ®Google Scholar
• MATTES CE, BELENDIUK GW, LYNCH TJ, BRADY RO, DRETCHEN KL: Butyrylcholinesterase: an enzyme antidote for cocaine intoxication. Addiction Biology (1998) 3:171–188.
   Web of Science ®Google Scholar
• NACHON F, NICOLET Y, VIQUIE N, MASSON P, FONTECILLA-CAMPS JD, LOCKRIDGE O: Engineering of a monomeric and low-glycosylated form of human butyrylcholinesterase: expression, purification, characterization and crystallization. Eur. j Biochem. (2002) 269:630–637.
   PubMedGoogle Scholar
• MATTES CE, LYNCH TJ, SINGH A et al.: Therapeutic use of butyrylcholinesterase for cocaine intoxication. Toxicol Appl. Pharmacol (1997) 145:372–380.
   PubMed Web of Science ®Google Scholar
• SUN H, PANG YP, LOCKRIDGE O, BRIMIJOIN S: Re-engineering butyrylcholinesterase as a cocaine hydrolase. Mol Pharmacol (2002) 62:220–224.
   PubMed Web of Science ®Google Scholar
• LAROCCA D, BURG MA, JENSEN-PERGAKES K, RAVEY PE, GONZALES AM, BAIRD A: Evolving phage vectors for cell targeted gene delivery. Curr. Pharm. Biotech. (2002) 3:45–57.
   PubMedGoogle Scholar
• SMITH GP: Filamentous fusion phage; novel expression vectors that display cloned antigens on the virion surface. Science (1985) 228:1315–1317.
   PubMed Web of Science ®Google Scholar
• CARLTON RM: Phage therapy: past history and future prospects. Arch. Immunol Ther. Exp. (Wdrsz) (1999) 47:267–274.
   PubMedGoogle Scholar
• SMITH HW, HUGGINS RB: Successful treatment of experimental E. coli infections in mice using phage: Its general superiority over antibiotics. J. Gen. MicrobioL (1982) 128:307–318.
   Google Scholar
• SLOPEK S, WEBER-DABROWSKA B, DABROWSKI M, KUCHAREWICZ-KRUKOWSKI A: Results in bacteriophage treatment of suppurative bacterial infections in the years 1981-1986. Arch. Immunol Ther. Exp. (1986) 35:569–583.
   Web of Science ®Google Scholar
• STONE R: Stalin's forgotten cure. Science (2002) 298:728–731.
   PubMed Web of Science ®Google Scholar
• PASQUALINI R, RUOSLAHTI E: Organ targeting in vivo using phage display peptide libraries. Nature (1996) 380:364–366.
   PubMed Web of Science ®Google Scholar
• ••A report describing the stability of phageonce injected into live animals.
   Google Scholar
• ESSLER M, RUOSLAHTI E: Molecular specialization of breast vasculature: a breast-homing phage-displayed peptide binds to aminopeptidase P in breast vasculatures. Proc. Natl. Acad. Sci. USA (2002) 99:2252–2257.
   PubMed Web of Science ®Google Scholar
• DABROWSKA K, SWITALA-JELEN K, OPOLSKI A, WEBER-DABROWSKA B, GORSKI A: Bacteriophage penetration in vertebrates. J. And MicrobioL (2005) 98:7–13.
   Web of Science ®Google Scholar
• FRENKEL D, SOLOMON B: Filamentous phage as vector-mediated antibody delivery to the brain. Proc. Natl. Acad. Sci. USA (2002) 99:5675–5679.
   PubMed Web of Science ®Google Scholar
• ••The first reported example of using phageas a vehicle for transporting displayed proteins into the CNS.
   Google Scholar
• GAO C, MAO S, LO CH, WIRSCHING P, LERNER RA, JANDA KD: Making artificial antibodies: a format for phage display of combinatorial heterodimeric arrays. Proc. Natl. Acad. Sci. USA (1999) 96:6025–6030.
   PubMed Web of Science ®Google Scholar
• GAO C, MAO S, KAUFMANN G, WIRSCHING P, LERNER RA, JANDA KD: A method for the generation of combinatorial antibody libraries using pIX phage display. Proc. Natl. Acad. Sci. USA (2002) 99:12612–12616.
   PubMed Web of Science ®Google Scholar
• CARRERA MR, KAUFMANN GF, MEE JM, MEIJLER MM, KOOB GF, JANDA KD: Treating cocaine addiction with viruses. Proc. Natl. Acad. Sci. USA (2004) 101:10416–10421.
   PubMed Web of Science ®Google Scholar
• ••A recent paper disclosing the ability ofphage-displayed antibodies to enter the CNS and abrogate some of the effects of cocaine exposure.
   Google Scholar
• BARBAS CF, BURTON DR, SCOTT JK, SILVERMAN GJ: Phage Display: A Laboratory Manual. Barbas CF, Burton DR, Scott JK, Silverman GJ (Eds), Cold Spring Harbor Laboratory Press, Plainview, NY, USA (2001).
   Google Scholar
• LYON M, ROBBINS TW: The action of central nervous system stimulant drugs: a general theory concerning amphetamine effects. In: Current Developments In Psychopharmacology VoL 2 Essman W, Valzelli L (Eds), Spectrum, New York, USA (1975):89–163.
   Google Scholar
• ILLUM L, DAVIS SS: Polymeric lamellar substrate particles for intranasal vaccination. Adv. Drug Deliv. Rev. (2001) 51:97–111.
   PubMed Web of Science ®Google Scholar
• JONES N: The nose and paranasal sinuses physiology and anatomy. Adv. Drug. Deliv. Rev. (2001) 51:5–19.
   PubMed Web of Science ®Google Scholar
• HANEY M, KOSTEN TR: Therapeutic vaccines for substance dependence. Expert Rev. Vaccines (2004) 3:11–18.
   PubMedGoogle Scholar
• CHEN L, ZURITA AJ, ARDELT PU, GIORDANO RJ, ARAP W, PASQUALINI R: Design and validation of a bifunctional ligand display system for receptor targeting. Chem. Biol. (2004) 11:1081–1091.
   PubMed Web of Science ®Google Scholar
• BRESLER MM, ROSSER SJ, BASRAN A, BRUCE NC: Gene cloning and nucleotide sequencing and properties of a cocaine esterase from Rhodococcus sp. strain MB1. Appl. Environ. Microbiol. (2000) 66:904–908.
   PubMed Web of Science ®Google Scholar